ORIGINAL RESEARCH article
Front. Oral Health, 23 April 2021
Sec. Oral Cancers
Volume 2 - 2021 | https://doi.org/10.3389/froh.2021.653104
RETRACTED: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
- AD
Alex Dobriyan 1
- IG
Iris Gluck 2,3
- EA
Eran Alon 3,4
- IB
Iris Barshack 3,5
- RY
Ran Yahalom 1
- MV
Marilena Vered 5,6*
1. Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
2. Head and Neck Cancer Unit, The Chaim Sheba Medical Center, Institute of Oncology, Tel Hashomer, Israel
3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
4. Department of Otolaryngology—Head and Neck Surgery, The Chaim Sheba Medical Center, Tel Hashomer, Israel
5. The Chaim Sheba Medical Center, Institute of Pathology, Tel Hashomer, Israel
6. Department of Oral Pathology, Oral Medicine and Maxillofacial Imaging, School of Dentistry, Tel Aviv University, Tel Aviv, Israel
Summary
Citation
Dobriyan A, Gluck I, Alon E, Barshack I, Yahalom R and Vered M (2021) RETRACTED: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings. Front. Oral. Health 2:653104. doi: 10.3389/froh.2021.653104
Received
13 January 2021
Accepted
22 March 2021
Published
23 April 2021
Volume
2 - 2021
Edited by
Ricardo D. Coletta, Campinas State University, Brazil
Reviewed by
Tine M. Søland, University of Oslo, Norway; Luiz Alcino Gueiros, Federal University of Pernambuco, Brazil
Updates
This article was submitted to Oral Cancers, a section of the journal Frontiers in Oral Health
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.